MINC‑sunitinib
Renal cell carcinoma
PreclinicalActive
Key Facts
About Suntec Medical
SunTec uses EGCG‑based nanocomplexes to deliver multi‑target immunotherapies for hard‑to‑treat cancers and CNS diseases.
View full company profileTherapeutic Areas
Other Renal cell carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Precision Oncology - RCC | ReviveMed | Discovery |
| Lenvatinib (LENVIMA) | Eisai | Regulatory Review |
| Cabozantinib | Exelixis | Phase 3 |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| Casdatifan (AB521) | Arcus Biosciences | Phase 3 |
| XmAb®819 | Xencor | Phase 1 |